Pharmaceuticals

Try Jim Cramer's Action Alerts PLUS
CLICK HERE NOW

ADHD Drugs Catch a Break

03/23/06 - 01:06 PM EST

Robert Steyer

Drug company investors breathed a sigh of relief Thursday after a group of medical experts said the Food and Drug Administration shouldn't impose a black box warning on treatments for attention deficit hyperactivity disorder.

A black box warning is the FDA's strongest alert, and it usually leads to depressed sales for drugs that carry the warning. However, the panel of outside advisers said labels for ADHD drugs should clearly describe their potential for psychiatric and cardiovascular risks.

The advisory panel, which met for about 11 hours Wednesday, didn't take a formal vote. The consensus opinion contrasted with a vote last month of another FDA committee. That panel voted 8-7, with one abstention, to recommend a black box warning about cardiovascular risks for all but one ADHD drug on the market. The FDA isn't bound by its advisory panels' suggestions.

The latest committee comprised mostly experts in pediatrics, adolescent medicine and psychiatry. Most advisers at last month's panel specialize in risk management, epidemiology and medical administration.

Great and Small

The debate among the experts and within the FDA is being closely watched by some of the world's biggest companies, as well as by midsized and small drugmakers whose existing or experimental ADHD drugs are crucial to future sales and the growth of their stock.

The biggest ADHD companies -- Novartis NVS, Johnson & Johnson JNJ and Eli Lilly LLY -- can absorb unfavorable news more easily than the other companies.

An across-the-board black box warning would have a more profound effect on the companies like Cephalon CEPH, whose Sparlon is being reviewed today by another FDA panel. Cephalon's stock has been halted pending the panel's vote on the drug designed for children ages 6 to 17.

The company with the most to win or lose from the FDA's verdict is Shire PLC SHPGY. Shire sells Adderall XR and Adderall, which are prescribed for children and adults. It also has agreements with two other companies for experimental ADHD medications.

Previous «
1 2 3

Pharmaceuticals


03/22/06
Cephalon Overcomes Sparlon Scare

Anxious investors are finally about to learn what an FDA panel thinks of the ADHD drug.


03/01/06
Cephalon's Next Big Thing

The experimental ADHD drug Sparlon is about to get a hearing before an FDA panel.


02/23/06
Shire's Search for Tranquility

The company hopes its future won't be rocky, what with new product launches and ADHD uncertainty.


02/09/06
ADHD Drugs May Get Black Box

An FDA advisory panel recommends the drugs carry the strictest warning.


12/05/05
Big Day for Noven Pharma

The company's shares rise more than 30% after its ADHD patch gets an upbeat medical review.


05/19/08
Cramer on Top Searched Stocks: Yahoo!

Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.


05/17/08
Jim Cramer's Best Blogs

Catch up on his thinking on the hottest topics of the past week.


04/26/08
Coming Week: Make or Break

Investors will have to deal with a Fed meeting and another flood of earnings and economic data.


05/19/08
Top Rocket Stocks: Ensco

Ensco International and Echelon have the potential to move higher in coming days.


04/28/08
Monday's Analysts' Upgrades, Downgrades

See who made what calls.


05/19/08
Telecom Giants See a Savior in Video

The addition of video is helping telecom companies compete against cable and satellite companies.


05/19/08
Contract Expiration Tempers Oil's Rise

The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.


05/19/08
Analysts' Upgrades, Downgrades: Amazon

See who made what calls.


Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Sign up for our FREE newsletters now.

Keep on top of the market and the critical information you need to make more profitable investing decisions.

  • Cramer's Daily Booyah!
  • Before the Bell

Privacy Policy

See All Free Newsletters

Premium Stock Ideas
Access Action Alerts Plus to find out Cramer’s latest picks now!